| 2025-11-14 |
详情>>
股本变动：
变动后总股本152.66万股
变动原因 ▼▲
- 原因：
- a one-for-nineteen reverse split of the Company's common stock
|
| 2025-11-14 |
详情>>
拆分方案：
每19.0000合并分成1.0000股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.8美元,归母净利润-2286.2万美元,同比去年增长-611.33%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘前发布财报
|
| 2025-08-28 |
股东大会：
将于2025-10-16召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to serve until the 2028 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified;
2.To authorize the Company’s Board of Directors to amend the amended and restated certificate of incorporation of the Company, as amended, to effect a reverse stock split of the Company’s outstanding common stock, par value $0.0001 per share, at any ratio between at least 1-for-5 and less than 1-for-20, to be effected at such time as the Company’s Board of Directors shall determine, in its sole discretion, at any time before October 16, 2026;
3.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025;
4.To approve the adjournment or postponement of the Annual Meeting, if necessary, to continue to solicit votes for Proposals No. 1 through 3;
5.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.5美元,归母净利润-1369.6万美元,同比去年增长-6.53%
|
| 2025-07-14 |
复牌提示：
2025-07-14 09:31:28 停牌，复牌日期 2025-07-14 09:36:28
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.33美元,归母净利润-765.9万美元,同比去年增长55.80%
|
| 2025-04-14 |
详情>>
内部人交易：
Solomon Jonathan Eitan等共交易3笔
|
| 2025-03-27 |
股东大会：
将于2025-04-21召开股东大会
会议内容 ▼▲
- 1.To approve the exercise of certain warrants into shares of common stock of the Company, par value $0.0001 per share, in accordance with Section 713 of the NYSE American LLC Listed Company Guide, previously issued in private placements (i) pursuant to that certain Securities Purchase Agreement, dated February 25, 2025, by and among the Company and the investors signatory thereto and (ii) pursuant to that certain Inducement Letter, dated February 25, 2025, by and among the Company and the holders signatory thereto ;
2.To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposal No. 1 ;
3.To transact any other business that may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2025-03-25 |
详情>>
业绩披露：
2024年年报每股收益-1.47美元,归母净利润-1772.7万美元,同比去年增长32.26%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.32美元,归母净利润-321.4万美元,同比去年增长84.46%
|
| 2024-08-23 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.19美元,归母净利润-1285.6万美元,同比去年增长-0.66%
|
| 2024-06-17 |
股东大会：
将于2024-07-09召开股东大会
会议内容 ▼▲
- 1.To approve the conversion of 256,887 shares of our Series X Non-Voting Convertible Preferred Stock, par value $0.0001 per share, and the exercise of certain warrants issued in connection with the acquisition of Adaptive Phage Therapeutics, Inc., a Delaware corporation, that closed on March 15, 2024 and a concurrent private placement offering that closed on March 15, 2024 into shares of our common stock, par value $0.0001 per share (“Common Stock”), in accordance with Section 713 of the NYSE American LLC Listed Company Guide (“Proposal No. 1”);
2.To approve the amendment and restatement of the Company’s 2019 Omnibus Long-Term Incentive Plan (“Proposal No. 2”);
3.To approve an amendment to our amended and restated certificate of incorporation, as amended, to increase the number of authorized shares of the Common Stock from one hundred and twenty million (120,000,000) shares of Common Stock to seven hundred fifty million (750,000,000) shares of Common Stock (“Proposal No. 3”);
4.To elect two Class I directors to serve until the 2027 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified (“Proposal No. 4”);
5.To approve, on a nonbinding advisory basis, the compensation of the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and the narrative discussion related thereto (“Proposal No. 5”);
6.To conduct a nonbinding advisory vote on the frequency (every one, two or three years) of future advisory votes on the compensation of the Company’s named executive officers (“Proposal No. 6”);
7.To authorize the Company’s Board of Directors to amend the amended and restated certificate of incorporation, as amended, of the Company to effect one reverse stock split of the Company’s outstanding Common Stock at any ratio between 1-for-5 and 1-for-10 at such time as our Board of Directors shall determine, in its sole discretion, any time before July 9, 2025 (“Proposal No. 7”);
8.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 (“Proposal No. 8”);
9.To approve the adjournment or postponement of the Annual Meeting, if necessary, to continue to solicit votes for Proposals No. 1 through 8 (“Proposal No. 9”);
10.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-05-20 |
详情>>
业绩披露：
2024年一季报每股收益-0.28美元,归母净利润-1732.7万美元,同比去年增长-172.39%
|
| 2024-04-04 |
详情>>
业绩披露：
2023年年报每股收益-0.51美元,归母净利润-2616.9万美元,同比去年增长7.59%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.43美元,归母净利润-2067.8万美元,同比去年增长7.82%
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.31美元,归母净利润-1277.2万美元,同比去年增长18.39%
|
| 2023-07-28 |
股东大会：
将于2023-08-28召开股东大会
会议内容 ▼▲
- 1.For the approval of an amendment to the Incentive Plan allowing the Board to effect one or more Option Exchanges
2.For the authorization of our Board to amend the Certificate of Incorporation to effect one reverse stock split of our outstanding Common Stock, $0.0001 par value per share, at any ratio between 1-for-5 and 1-for-10 at such time as our Board shall determine, in its sole discretion, any time before August 28, 2024
|
| 2023-05-01 |
股东大会：
将于2023-06-20召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to serve until the 2026 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified;
2.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023;
3.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2023-03-22 |
股东大会：
将于2023-04-24召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of up to 24,632,245 shares of Common Stock, par value $0.0001 each (“Shares”), composed of Shares and Shares underlying pre-funded warrants, in accordance with the Securities Purchase Agreement dated February 22, 2023, in order to comply with the listing rules of the NYSE American; and
|
| 2022-07-07 |
股东大会：
将于2022-08-24召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to serve until the 2025 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified;
2.To approve an amendment to the amended and restated certificate of incorporation of the Company to increase the number of authorized shares of Common Stock from sixty million (60,000,000) shares, par value $0.0001 per share to one hundred and twenty million (120,000,000) shares of Common Stock, par value $0.0001 per share;
3.To authorize the Company’s Board of Directors to amend the amended and restated certificate of incorporation of the Company to effect one reverse stock split of the Company’s outstanding Common Stock, $0.0001 par value per share, at any ratio between 1-for-5 and 1-for-10 at such time as our Board of Directors shall determine, in its sole discretion, any time before August 24, 2023;
4.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022;
5.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to serve until the 2024 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified;
2.To ratify the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021;
3.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-04-21 |
股东大会：
将于2020-06-03召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to serve until the 2021 annual meeting of stockholders two Class II directors to serve until the 2022 annual meeting of stockholders, and three Class III directors to serve until the 2023 annual meeting of stockholders, and in each case, until their successors are duly elected and qualified;
2.To ratify the appointment of Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To transact any other business that may properly come before the meeting or any adjournment or postponement thereof.
|